Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer

TME Pharma

Status and phase

Completed

Phase 2

Conditions

Anemia of Chronic Disease

Treatments

Drug: NOX-H94

Drug: Placebo solution

Study type

Interventional

Funder types

Industry

Identifiers

NCT01691040

2012-001525-27 (EudraCT Number)

SNOXH94C201

Details and patient eligibility

About

This study is conducted to determine the safety, tolerability, and efficacy of NOX-H94 in patients with anemia of chronic disease (ACD). Furthermore, this study is intended to provide data needed to correlate plasma concentrations of NOX-H94 with its efficacy and to choose the appropriate dose and dose schedule of subsequent efficacy studies.

Some chronic diseases, e.g. tumors, inflammation, renal disease, are associated with high hepcidin concentrations in the blood. These hepcidin concentrations cause a reduction in iron concentrations in the blood and subsequently impair formation of red blood cells. Treatment with NOX-H94 is expected to inhibit this patho-mechanism by binding and inactivating hepcidin.

Enrollment

12 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Written informed consent
Female or male aged >18 years
Clinically significant anemia of chronic disease (ACD) attributed to histologically or cytologically proven malignancy, either hematological or solid tumor, of any grade or stage: Hemoglobin (Hb) 7.0 g/dL to 10 g/dL, Transferrin saturation (TSAT) <50%, Serum iron <50 µg/dL (SI: <9.0 µmol/L), AND Ferritin >30 ng/mL (SI: >30 µg/L)
Previous treatment with systemic anti-cancer therapy / regimen
Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
Estimated life expectancy ≥12 weeks
Men must agree to follow effective contraception methods during treatment and for 3 months after completion of treatment. Women of childbearing potential must agree to use two forms of effective contraception during treatment and for 3 months after completion of treatment.

Exclusion criteria

Inability to personally provide written informed consent or to understand and collaborate throughout the study
History of pure red cell aplasia, thalassemia major or sickle cell disease History of anemia unrelated to cancer <10 g/dL within 6 months prior to screening
Uncorrected iron deficiency
Regular need for blood transfusions at intervals <6 weeks
Acute or myeloid leukemia
Known or suspected chronic bleeding
Tumor with gastro-intestinal involvement without negative test for fecal occult blood
Suspected or known history of hemochromatosis
Known infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Impaired liver function with bilirubin ≥2.0 mg/dL (26 μmol/L), AST or ALT ≥2 times upper limit
History or risk of significant hepatic disease, e.g. chronic alcohol abuse, hepatic steatosis, hepatic cirrhosis, or organ transplantation
Severe renal impairment: estimated glomerular filtration rate (eGFR) <30 mL/min (Cockcroft-Gault)
Known central nervous system malignancy or metastasis
Significant cardiac disease (e.g. uncontrolled hypertension: systolic blood pressure [BP] >150 mmHg or diastolic BP >100 mmHg; myocardial infarction or unstable angina pectoris) within 6 months prior to screening
Positive pregnancy test (serum ß-hCG at screening, urine pregnancy test prior to first treatment) or lactation
Previous participation in this study or treatment with an investigational agent <21 days prior to treatment start
Hemolysis or bleeding >500 mL (measured or estimated) within 6 weeks prior to treatment start
Treatment with erythropoiesis-stimulating agents (ESAs) or red blood cell (RBC) transfusions <21 days prior to treatment start
Cytotoxic anti-tumor treatment <21 days prior to treatment start or planned during the anticipated study period (within 3 months from treatment start or randomization). Maintenance therapy is permitted throughout the study (e.g. lenalidomide, interferon)